NEWS

NEWS 2023

News Highlights

Check this page for recent news from Appili Therapeutics.

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024

Read More

Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan

Read More

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024

Read More

Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy

Read More

Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update

Read More

Appili Therapeutics Presents at the 10th International Tularemia Conference

Read More

Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension

Read More

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024

Read More

Appili Therapeutics Announces Bridge Loan from Bloom Burton & Co.

Read More

Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results

Read More

­­Appili Therapeutics Announces Issuance of Patent  for ATI-1501 Liquid Oral Reformulation of Metronidazole

Read More

Appili Therapeutics Secures Contract for ATI-1701 Funding from the U.S. Air Force Academy

Read More

Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Read More

Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer

Read More

Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings

Read More

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023

Read More

Appili Therapeutics Announces that FDA accepts the ATI-1501 NDA

Read More

Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program

Read More

Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole

Read More